HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines.
Esperanza
E
Martín-Sánchez
Margarita
M
Sánchez-Beato
María Elena
ME
Rodríguez
Beatriz
B
Sánchez-Espiridión
Cristina
C
Gómez-Abad
James R
JR
Bischoff
Miguel A
MA
Piris
Africa
A
García-Orad
Juan F
JF
García
D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006689:Hodgkin Disease / Q000473:pathology*; D006801:Humans; D051573:Proto-Oncogene Proteins c-pim-1 / Q000037:antagonists & inhibitors; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D051573:Proto-Oncogene Proteins c-pim-1; C406031:proto-oncogene proteins pim